Market Exclusive

Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Submission of Matters to a Vote of Security Holders

Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07. Submission of Matters To a Vote of Security Holders

On October26, 2017, Array BioPharma Inc. (the “Company”) held its Annual Meeting. There were 137,196,593 shares of common stock represented in person or by valid proxies at the Annual Meeting and entitled to be voted, representing 79.9% of the 171,766,223 shares of common stock outstanding as of the August30, 2017 record date. The stockholders voted on four proposals at the Annual Meeting. The proposals are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission dated September13, 2017. The following is a tabulation of the final voting results for each of the proposals presented and voted on at the Annual Meeting.

Proposal 1: The Company’s stockholders elected three ClassII Directors, each to serve for a three-year term expiring at the 2020 annual meeting of stockholders and until their respective successors have been duly elected and qualified. The votes regarding this proposal were as follows:

VotesFor

Votes Withheld

Broker Non-Votes

Kyle Lefkoff

114,129,342

2,170,830

20,896,421

Shalini Sharp

115,249,176

1,050,996

20,896,421

Ron Squarer

114,139,985

2,160,187

20,896,421

Proposal 2: The Company’s stockholders approved the advisory vote on executive compensation. The votes regarding this proposal were as follows:

VotesFor

VotesAgainst

Votes Abstained

Broker Non-Votes

113,136,559

2,932,218

231,395

20,896,421

Proposal 3: The Company’s stockholders approved the holding an advisory vote of stockholders on executive compensation on an annual basis. The votes regarding this proposal were as follows:

OneYear

TwoYears

ThreeYears

Abstain

111,137,501

125,816

4,916,041

120,814

Proposal 4: The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending June30, 2018. The votes regarding this proposal were as follows:

VotesFor

VotesAgainst

Votes Abstained

Broker Non-Votes

136,658,227

112,948

425,418

About Array BioPharma Inc. (NASDAQ:ARRY)
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

Exit mobile version